###begin article-title 0
Three allele combinations associated with Multiple Sclerosis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Multiple sclerosis (MS) is an immune-mediated disease of polygenic etiology. Dissection of its genetic background is a complex problem, because of the combinatorial possibilities of gene-gene interactions. As genotyping methods improve throughput, approaches that can explore multigene interactions appropriately should lead to improved understanding of MS.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 208 211 208 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 213 215 213 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT</italic>
###xml 217 225 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1</italic>
###xml 227 232 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 236 242 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
286 unrelated patients with definite MS and 362 unrelated healthy controls of Russian descent were genotyped at polymorphic loci (including SNPs, repeat polymorphisms, and an insertion/deletion) of the DRB1, TNF, LT, TGFbeta1, CCR5 and CTLA4 genes and TNFa and TNFb microsatellites. Each allele carriership in patients and controls was compared by Fisher's exact test, and disease-associated combinations of alleles in the data set were sought using a Bayesian Markov chain Monte Carlo-based method recently developed by our group.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
We identified two previously unknown MS-associated tri-allelic combinations:
###end p 7
###begin p 8
###xml 4 13 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1*</italic>
###xml 16 21 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 28 34 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4*</italic>
###xml 44 48 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF*</italic>
###xml 55 59 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF*</italic>
###xml 63 69 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4*</italic>
###xml 178 182 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 259 263 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5</italic>
###xml 272 276 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
-509TGFbeta1*C, DRB1*18(3), CTLA4*G and -238TNF*B1,-308TNF*A2, CTLA4*G, which perfectly separate MS cases from controls, at least in the present sample. The previously described DRB1*15(2) allele, the microsatellite TNFa9 allele and the biallelic combination CCR5Delta32, DRB1*04 were also reidentified as MS-associated.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
These results represent an independent validation of MS association with DRB1*15(2) and TNFa9 in Russians and are the first to find the interplay of three loci in conferring susceptibility to MS. They demonstrate the efficacy of our approach for the identification of complex-disease-associated combinations of alleles.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 948 953 948 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 957 963 957 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/DQA1*</italic>
###xml 967 973 967 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/DQB1*</italic>
###xml 1082 1083 1082 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1455 1457 1455 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 424 429 <span type="species:ncbi:9606">human</span>
Investigation of polygenic human diseases, which arise from the combined contribution of multiple independently acting and/or interacting polymorphic genes, remains a great challenge [1-3]. A common constituent of the complexity that underlies the susceptibility to polygenic diseases is heterogeneity [3,4]. MS [MIM 126200] is an immune-mediated hereditary disease [5,6], and can be considered as a prototype for polygenic human diseases [4]. The results of linkage-based whole genome screen studies [7,8] and a global meta-analysis [9,10] document the concept that MS is the result of the interaction of several genes. The effects of individual genes are small or modest, making association studies more informative than others because of their greater statistical power [1,11]. Association testing is extensively employed in candidate-gene studies, which are usually conducted in population-based case-control studies. To date, the HLA class II DRB1*1501/DQA1*0102/DQB1*0602 (DR2) haplotype is the only region repeatedly confirmed as being associated with MS in most Caucasians [5,10]. Other candidate genes for MS predisposition studies have been selected mainly because their encoded proteins are involved in autoimmune pathogenesis. These include genes for immunorelevant molecules such as cytokines, cytokine receptors, immunoglobulins, T-cell receptors and specific adapter protein, potential autoantigens of the myelin sheath, ICAM1, and others [12].
###end p 12
###begin p 13
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1294 1296 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1099 1107 <span type="species:ncbi:9606">patients</span>
Some studies searched for candidate gene combinations as MS risk factors; however, these studies have not yet extended beyond MS associations with alleles of each candidate gene coupled with HLA DRB1 alleles [13-19]. To examine the possibility that the combined effect of definite genes is a risk factor for a polygenic disease, it is necessary to explore a massive number of potential combinations of allelic variants identified at candidate-gene polymorphic loci. This number grows exponentially with the number of candidate variants that may interact, causing computational and statistical restrictions on the use of standard enumerational methodologies. In a recent paper [20], we described a novel algorithm based on Markov chain Monte Carlo exploration using a Bayesian statistical basis, APSampler, which allows the exploration of genotypes tied to phenotypic trait levels to identify possible combinations of allelic variants at multiple loci that could affect disease development. The aim of this study is to simultaneously examine multiple candidate genes in single groups of unrelated MS patients and healthy unrelated controls, all of Russian descent, and to search for disease-associated combinations of allelic variants at multiple loci using our novel nonparametric methodology [20].
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Subjects and DNA samples
###end title 15
###begin p 16
###xml 115 117 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 47 50 <span type="species:ncbi:9606">men</span>
###xml 59 64 <span type="species:ncbi:9606">women</span>
###xml 331 334 <span type="species:ncbi:9606">men</span>
###xml 343 348 <span type="species:ncbi:9606">women</span>
###xml 646 658 <span type="species:ncbi:9606">participants</span>
Two hundred eighty six unrelated patients (110 men and 176 women, mean age 33 +/- 12 years) had a diagnosis of MS [21]. Of these 187 had a relapsing-remitting MS course, 39 a primary progressive MS course, and 60 were secondary progressive. The mean age at onset was 23 +/- 9 years. Three hundred sixty-two unrelated controls (203 men and 159 women, mean age 30 +/- 11 years) were studied. All controls were free of acute or chronic internal and neurological diseases as determined by physical examinations. All subjects were living in the Moscow area; both their parents were ethnic Russians. Informed consent to the study was obtained from all participants and was approved by the local Ethical Committee. Blood was adjusted to 25 mM EDTA. Genomic DNA was isolated from 5 mL of peripheral blood by phenol-chloroform extraction using standard procedures.
###end p 16
###begin title 17
Genotyping
###end title 17
###begin p 18
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Investigated polymorphic loci (including SNPs, repeat polymorphisms, and one insertion/deletion) and the numbers of genotyped MS patients and controls for each marker are presented in Table 1.
###end p 18
###begin p 19
Polymorphous loci at or near genes of immune response included in the database
###end p 19
###begin p 20
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 186 189 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT </italic>
###xml 215 224 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1 </italic>
###xml 266 270 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
Abbreviations used: CCR5 - CC chemokine receptor 5 gene; CTLA4 - cytotoxic T-lymphocyte-associated protein 4 gene; DRB1 - major histocompatibility complex class II DR beta-chain gene 1; LT - lymphotoxin alpha gene; TGFbeta1 - transforming growth factor beta-1 gene; TNF - tumor necrosis factor gene; PCR - polymerase chain reaction; RFLP - restriction fragment length polymorphism; SSO - sequence-specific oligonucleotides; SSP - sequence-specific primers; ins - insertion; wt - wild type.
###end p 20
###begin p 21
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
* All positions of the SNPs are indicated relative to transcriptional start sites except CTLA4 SNP +49, where +49 is the position from translational start site.
###end p 21
###begin p 22
** RefSNP IDs (rs#) are given for SNPs submitted in PubMed NCBI dbSNP.
###end p 22
###begin title 23
HLA DRB1 gene
###end title 23
###begin p 24
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
For genomic typing of the DRB1 gene, a sequence-specific primer (PCR-SSP) technique was used. The two-step PCR allowed amplification of all known DRB1 alleles and their separation into groups corresponding to the specificities from DR1 to DR18 [22].
###end p 24
###begin title 25
TNFa and TNFb microsatellites
###end title 25
###begin p 26
###xml 42 44 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 141 144 141 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT </italic>
###xml 228 230 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 372 374 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
For a length polymorphism analysis of (AC)n and (TC)n microsatellites, designated as TNFa and TNFb, which are located 3.5 kb upstream of the LT gene, nested PCR was used. The second PCR was carried out in the presence of [alpha-32P]dATP, then PCR products were treated by the Klenow fragment of DNA polymerase I and electrophoresed in an 8% polyacrylamide sequencing gel [23].
###end p 26
###begin title 27
SNPs in TNF gene
###end title 27
###begin p 28
###xml 365 368 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 372 374 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 442 444 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 586 587 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 640 641 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 828 830 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1174 1175 1167 1168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1176 1177 1169 1170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1179 1180 1172 1173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1224 1225 1217 1218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Genotyping of the -238A-->G polymorphism was performed by analysis of restriction fragment length polymorphism of PCR products (PCR-RFLP method). PCR amplification was carried out using the exactly homologous forward primer, while the reverse primer contained two sequence mismatches, which made it possible to evaluate mutation status using the restriction enzyme BamHI [24]. Analysis of the -308G-->A polymorphism was performed by PCR-SSP [25]. For genotyping of the -376A-->G polymorphism, the PCR-SSP method was also used. The forward primers are 5'-CTT TTT CCT GCA TCC TGT CTG GAA A-3' for -376A and 5'-CTT TTT CCT GCA TCC TGT CTG GAA G-3' for -376G, the common reverse primer was 5'-TTC TGT CTC GGT TTC TTC TCC ATC G-3'. These primers were constructed using free on-line software GeneFisher-Interactive PCR Primer Design [26]. PCR was performed in 10 muL volumes containing 0.1 units of Taq polymerase (from SileksM, Moscow, Russia), 200 ng of genomic DNA, 5 pmol of the reverse PCR primer, 5 pmol of the sequence-specific PCR primer for allele A or 2.5 pmol of the sequence-specific PCR primer for allele G, four dNTPs (each at 5 mM), 70 mM Tris HCl pH 9.0, 20 mM (NH4)2SO4, 0.025% Tween 20, 0.025% NP-40, 1.0 mM MgCl2. Thermocycling consisted of 35 cycles of 92degreesC for 60 s, 60degreesC for 90 s, 72degreesC for 90 s. The resulting fragment length was 238 bp.
###end p 28
###begin title 29
SNPs in LT gene
###end title 29
###begin p 30
###xml 225 228 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 230 232 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 331 334 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alw</italic>
###xml 339 342 333 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Asp</italic>
###xml 377 379 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Genotyping of the +252G-->A and +319C-->G polymorphisms was performed by PCR-RFLP method. For analysis of the SNP +252G-->A, PCR amplification was performed and the product aliquots were digested using the restriction enzyme NcoI[27]. In parallel, other aliquots of the same PCR products were digested using the restriction enzyme Alw21I (AspHI) for analysis of SNP +319C-->G [24].
###end p 30
###begin title 31
SNPs in TGFbeta1 gene
###end title 31
###begin p 32
###xml 35 44 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1 </italic>
###xml 428 430 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 484 486 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 831 833 810 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
For genotyping of five SNPs in the TGFbeta1 gene, four PCR fragments were obtained (one PCR fragment was common for the SNP +869T-->C (10Leu-->Pro) and SNP +915G-->C (25Arg-->Pro)). Then resulting fragments were immobilized on Hybond-N+ membrane (Amersham Pharmacia Biotech) followed by hybridization with sequence-specific oligonucleotide probes (PCR-SSO method). PCR conditions, primers and probes were as those described in [28], hybridization procedure was modified according to [29] as follows. Prehybridization was performed for at least 2 h at 52degreesC in 3.0 M tetramethylammonium chloride (TMAC), 50 mM Tris HCl pH 8.0, 2 mM EDTA, 5xDenhardt's solution, 0.1% SDS, 100 ng/mL heat-denatured herring sperm DNA and 10-20 pmol/mL of unlabeled oligonucleotide probe specific for the other allele. Then 10-20 pmol/mL of [gamma-32P]ATP-labeled allele-specific oligonucleotide was added and hybridization was performed for at least 2 h at 52degreesC. The membranes were washed at room temperature in 2xSSC for 30 min followed by 2 x 15 min in 2xSSC, 0.1% SDS. Then the membranes were washed twice at 58degreesC in 3.0 M TMAC, 50 mM Tris HCl pH 8.0, 2 mM EDTA, 0.1% SDS, rinsed in 2xSSC and autoradiographed.
###end p 32
###begin title 33
32 base pair deletion in CCR5 gene
###end title 33
###begin p 34
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
CCR5 genomic typing was performed using one-step PCR with primers flanking the region of the 32-nucleotide deletion [30].
###end p 34
###begin title 35
SNP in CTLA4 gene
###end title 35
###begin p 36
###xml 30 36 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 105 108 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bst</italic>
###xml 113 115 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Genotyping of SNP +49A-->G in CTLA4 gene was performed by PCR-RFLP analysis using the restriction enzyme BstEII [31].
###end p 36
###begin title 37
Database
###end title 37
###begin p 38
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
The genotypes and personal data for all patients and controls were entered into a database, together with clinical characteristics for patients. Microsoft Visual FoxPro was used to develop a standalone database management system that was used for input and analysis of the data.
###end p 38
###begin title 39
Search algorithm
###end title 39
###begin p 40
###xml 33 35 33 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 222 235 222 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a posteriori </italic>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
We used the APSampler algorithm [20] that identifies combinations (patterns) of alleles at different loci that are potentially associated with a phenotypic trait. Here, we provide a brief description of the algorithm. The a posteriori probability for support of each pattern given the data is evaluated using a likelihood obtained from a battery of conditional rank sum statistics that insures that each pattern is evaluated after removing the effect of other patterns, as in a statistical adjustment for multiple regression. Each step of the algorithm is an update of a current set of allelic patterns by a variation of the Metropolis-Hastings algorithm [32,33]. The sets of patterns that receive high support from the data are stored as potential results. For each pattern, only those individuals that have all the pattern's alleles genotyped were considered. Thus the algorithm proceeded from incomplete genotypic information, temporarily omitting those individuals that cannot be unambiguously classified into the pattern carriers and non-carriers at a given step. The executable files for Win32 console and for FreeBSD, together with documentation, are available free to academic users (contact AVF or MFO).
###end p 40
###begin p 41
###xml 152 160 152 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori</italic>
In the current application to the MS case-control data, the prior probability that a locus has no effect on the phenotype was set to 0.99. This favored a priori the case in which each locus has no effect on phenotype, so that the search would not explore patterns with a very large number of alleles, which are unlikely to be reliably investigated in this data set. We looked for sets of 2 or 3 patterns.
###end p 41
###begin title 42
Statistical analysis
###end title 42
###begin p 43
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 518 520 518 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p-</italic>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 678 680 678 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p-</italic>
###xml 701 703 701 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p-</italic>
###xml 711 712 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 712 716 712 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">corr</italic>
###xml 712 716 712 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>corr</italic></sub>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
To compare allelic distributions in MS patients and controls and to verify the APSampler's results, we used Fisher's exact test. The analysis was performed using the GraphPad InStat software package and original computer scripts under Microsoft Visual FoxPro. As a statistical control for systematic genotyping error and population stratification, the expected genotype proportions according to the Hardy-Weinberg equilibrium were calculated and compared to observed genotypes. For polymorphic DRB1 and TNFa loci, the p-values were corrected for the number of comparisons (13 in case of DRB1 allele groups and 12 in case of TNFa alleles) according to the Bonferroni method. The p-values and corrected p-values (pcorr) were considered to be significant at a level smaller than 0.01. The odds ratio (OR) was calculated with a 95% confidence interval (CI).
###end p 43
###begin p 44
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
For the haplotype frequency estimation, for the linkage disequilibrium test, and for the Hardy-Weinberg disequilibrium test, the population genetics data-analyzing software Arlequin (version 2.0) [34] was used. We considered a linkage disequilibrium or a Hardy-Weinberg disequilibrium to be significant when the p-value from the Arlequin output was less than or equal to 0.05. For estimation of haplotype frequencies, the default parameters were used. To assess the significance of the APSampler-discovered patterns, we computed the Empirical Bayes false discovery rate, which is the estimated fraction of patterns unrelated to the phenotype among those that have a significance score as high or higher than the pattern reported [35]. The vector of disease labels was permuted in a balanced way by assigning the same number of diseased and healthy individuals to two groups generated by permutation. We repeated the permutation 100 times and examined all possible combinations with the same number of alleles as the pattern considered. For each permutation and each combination, we computed a test of association and counted the fraction of these tests that were larger than the observed test for the pattern.
###end p 44
###begin title 45
Results
###end title 45
###begin p 46
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 416 421 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 478 479 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 479 483 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">corr</italic>
###xml 479 483 479 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>corr</italic></sub>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 588 589 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 589 593 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">corr</italic>
###xml 589 593 589 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>corr</italic></sub>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 977 979 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1098 1115 1098 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional File 1</xref>
###xml 1140 1145 1140 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 1249 1254 1249 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 1363 1380 1363 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">Additional File 2</xref>
###xml 1403 1408 1403 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 1533 1536 1533 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1561 1563 1557 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT</italic>
###xml 1662 1664 1658 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1712 1719 1708 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT </italic>
###xml 1735 1739 1731 1735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 1751 1768 1747 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">Additional File 3</xref>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
###xml 839 847 <span type="species:ncbi:9606">patients</span>
###xml 1628 1636 <span type="species:ncbi:9606">patients</span>
Individuals were genotyped at polymorphic loci at or near genes of the immune response situated at chromosomes 2, 3, 6 and 19 (Table 1). The allelic carriership (phenotypic frequency) in case of biallelic candidate loci (Figure 1) did not differ significantly in MS patients and controls. The allelic distributions of polymorphic candidate loci showed a positive association of MS with a carriership of allele group DRB1*15(2), corresponding to serological specificity DR15(2) (pcorr<0.0001, OR = 3.1, CI is 2.1-4.6) (Figure 2A), and with a carriership of a TNFa*9 microsatellite allele (pcorr<0.01, OR = 7.9, CI is 1.8-35.0) (Figure 2B). The allelic distribution of the TNFb microsatellite, which is adjacent to TNFa, did not differ significantly in MS patients and controls (Figure 2C). It agreed with TNFa/TNFb haplotype frequencies in patients and controls, which were estimated from genotype data via the population genetics data-analyzing software Arlequin version 2.00 [34]. The predisposing TNFa9 allele was part of three different haplotypes: TNFa9/TNFb1, TNFa9/TNFb4 and TNFa9/TNFb5 [see Additional File 1]. Both the HLA class II DRB1 gene and the class III TNFa microsatellite map to 6p21 and were in linkage disequilibrium; however, the DRB1*15(2)/TNFa9 haplotype frequency estimated from genotype data by the Arlequin software did not exceed 1% [see Additional File 2]. This suggested that DRB1 *15(2) and TNFa9 represented two independent MS-predisposing markers. The fact that no alleles of the tumor necrosis factor (TNF) and lymphotoxin alpha (LT) genes, also located at 6p21, differed significantly between MS patients and controls (see Figure 1A) correlated with the lack of strong linkage of TNF/LT haplotypes with DRB1*15(2) [see Additional File 3] and TNFa9 (not shown).
###end p 46
###begin p 47
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phenotypic frequencies (%) of SNP alleles in Russian MS patients and healthy individuals</bold>
###xml 136 143 136 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</bold>
###xml 145 148 145 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A: </bold>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT </italic>
###xml 185 188 185 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 188 197 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF &#946;1</italic>
###xml 199 204 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 208 214 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 513 530 510 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">Additional File 4</xref>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Phenotypic frequencies (%) of SNP alleles in Russian MS patients and healthy individuals. The numbers of typed individuals are given in Table 1. A: TNF and LT gene polymorphic regions; B: TGF beta1, CCR5 and CTLA4 gene polymorphic regions. For each SNP, phenotypic frequencies of both alleles are shown on the same axis of a radar chart; thick lines join all common and all rare alleles of SNPs presented, and SNP allele names are indicated on the vertices. The same data are presented in Additional Table 1 [see Additional File 4].
###end p 47
###begin p 48
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phenotypic frequencies (%) of some polymorphous HLA loci in the Russian population</bold>
###xml 223 226 223 226 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A: </bold>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 236 239 236 239 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 260 263 260 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C: </bold>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">corr </italic>
###xml 314 319 314 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>corr </italic></sub>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Phenotypic frequencies (%) of some polymorphous HLA loci in the Russian population. MS patients are shown by white bars and healthy individuals are shown by grey bars. The numbers of typed individuals are given in Table 1. A: HLA DRB1. B: TNFa microsatellite. C: TNFb microsatellite. For significant differences, pcorr values are shown near the corresponding bars, which are shaded.
###end p 48
###begin p 49
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5</italic>
###xml 481 485 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 538 540 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 541 543 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 730 738 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1</italic>
###xml 746 751 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 816 821 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 882 885 872 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 894 897 884 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 912 918 902 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4*</italic>
###xml 1097 1098 1087 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1458 1459 1448 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1464 1466 1454 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1749 1750 1739 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1788 1789 1778 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1833 1834 1823 1824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1956 1960 1946 1950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 2041 2045 2031 2035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF*</italic>
###xml 2052 2056 2042 2046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF*</italic>
###xml 2111 2128 2101 2118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">Additional File 3</xref>
###xml 1695 1703 <span type="species:ncbi:9606">patients</span>
Application of the APSampler algorithm [20] identified five patterns that have a high probability of being associated with MS according to a multidimensional Wilcoxon-based criterion. All the patterns identified deal with carriership of alleles, without distinguishing homozygotes from heterozygotes. Two of the patterns were the single predisposing alleles DRB1*15(2) and TNFa9 discussed above, while the third pattern was a predisposing biallelic combination of CCR5Delta32 with DRB1*04, which was recently described for this data set [15,20]. Importantly, two new patterns comprising "trios" of allelic variants were also identified. The first pattern included the C allele of SNP -509 of the transforming growth factor beta1 (TGFbeta1) gene, DRB1*18(3), and the G allele of the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (trio 1). The second pattern included the alleles -238TNF*B1, -308TNF*A2 and again, CTLA4*G (trio 2). Fisher's exact test gave p < 0.01 for the association of MS with both patterns, ORs were equal to 18.0 (CI 1.0-330) for trio 1 and 17.4 (CI 1.1-300) for trio 2 (Table 2). To assess the probability that the trio patterns found were truly associated with MS, we also computed the false discovery rate, which was less than 0.003. The algorithm was intended to identify patterns as minimal allelic sets, in the sense that such a set provides stronger evidence of association with MS than any of its subsets. As shown above (Figures 1 and 2A), none of the alleles involved in the trios were an individual risk factor. For both trios, among individuals who have all the three alleles genotyped, the difference in phenotypic frequencies for two-element subsets between MS patients and healthy subjects was insignificant, with p-values always exceeding 0.025 (Table 2). So, both trios, which gain Fisher's test p-values less than 0.01, were correctly identified as minimal MS-associated allelic sets. The fact that two alleles of the TNF gene were required to form trio 2 was in agreement with the data suggesting that TNF*B1 and TNF*A2 are not parts of a single widespread haplotype [see Additional File 3].
###end p 49
###begin p 50
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Phenotypic frequencies (carriership) of the three-allele combinations (trios) and their two-element subsets in Russian MS patients and healthy individuals
###end p 50
###begin p 51
###xml 78 86 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1</italic>
###xml 88 93 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 97 103 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
* 99 MS patients and 154 controls were genotyped at these polymorphic loci of TGFbeta1, DRB1 and CTLA4 genes.
###end p 51
###begin p 52
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
** 126 MS patients and 87 controls were genotyped at these polymorphic loci of TNF and CTLA4 genes.
###end p 52
###begin p 53
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p-</italic>
#p-values considered to be significant are given in bold face.
###end p 53
###begin p 54
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">## </sup>
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
## OR (95% CI) values are shown for significant p-values.
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5</italic>
###xml 263 268 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 287 296 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1*</italic>
###xml 299 304 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 311 317 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4*</italic>
###xml 326 329 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 337 340 330 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 345 350 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Based on the results presented, several (partially overlapping) subgroups may be identified in the common group of Russian MS patients, depending on carriership of distinct minimal patterns of susceptibility including one (DRB1*15(2) or TNFa9), two (CCR5Delta32, DRB1*04) and three (-509TGFbeta1*C, DRB1*18(3), CTLA4*G or -238TNF*B1,-308TNF*A2, CTLA4*G) alleles of candidate genes. These results are evidence of the genetic heterogeneity of MS.
###end p 56
###begin p 57
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 366 370 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
MS associations with DRB1*15(2) and TNFa9 were previously identified in our studies of independent groups of ethnic Russians [36,37] and were replicated here for a new dataset of patients and control subjects. Thus, the HLA class II DRB1*15(2) is validated in this study as being associated with MS in Russians as in most other Caucasians. As follows from our data, DRB1*15(2) and TNFa9 represent two independent predisposing markers, in agreement with the proposal that two MS susceptibility loci exist within the MHC [5,38].
###end p 57
###begin p 58
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 497 501 497 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 612 614 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 627 629 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 639 641 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 652 654 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 684 686 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 787 792 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 808 812 802 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 862 872 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916; </italic>
###xml 885 887 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 931 934 921 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MBP</italic>
###xml 942 944 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1000 1005 990 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 1030 1032 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
In previous studies, identification of MS-predisposing combinations of allelic variants at multiple loci consisted in stratification of affected and unaffected individuals mostly according to the carriership of MS-predisposing DR2 haplotype or its constituents and a subsequent pair comparison of phenotypic frequencies of distinct alleles of another gene of interest in subgroups of MS patients and controls. This kind of analysis found reliable associations of MS in subgroups of DRB1*15(2) (or DQB1*0602)-positive or negative individuals with the carriership of some alleles of genes coding TCRbeta receptor [14], TGFbeta1 [16], CTLA4 [13], ICAM-1 [19] and interleukin 4 receptor [18]. In our recent studies, we have extended this approach and stratified individuals according to any DRB1 phenotypes. For DRB1*04-positive individuals, associations of MS with CCR5Delta 32 mutation [15] and with alleles of myelin basic protein (MBP) gene [17] were found. The latter association was found also for DRB1*05 positive individuals [17].
###end p 58
###begin p 59
###xml 230 238 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1</italic>
###xml 242 246 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 254 259 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 270 273 267 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 281 284 278 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 289 294 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 619 620 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 896 900 893 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 902 906 899 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5</italic>
###xml 908 916 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1</italic>
###xml 918 922 912 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 926 932 920 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
A novel nonparametric methodology used in this paper provides the capability to explore potential combinations of more than two allelic variants of polymorphic candidate genes. Two previously unknown tri-allelic combinations: -509TGFbeta1*C, DRB1*18(3), CTLA4*G and -238TNF*B1,-308TNF*A2, CTLA4*G, which perfectly separate cases from controls in the present sample, were identified. Importantly, at least within our data set, non-overlapping subgroups of individuals bearing predisposing trios 1 and 2 constitute about 5% and 9% of considered MS patients, respectively, and 0% of considered healthy controls (see Table 2). This suggests that carriership of these patterns might predict MS development. Due to the linkage disequilibrium of chromosomal loci, a genetic epidemiological approach cannot prove unambiguously that a disease-associated gene is causal. However, a biological role for the DRB1, CCR5, TGFbeta1, TNF and CTLA4 gene products in the pathogenesis of MS is plausible, and supports the idea that the genes are actual MS susceptibility genes.
###end p 59
###begin p 60
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4*</italic>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 899 900 893 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-</italic>
###xml 903 912 897 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1*</italic>
###xml 941 942 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-</italic>
###xml 945 954 936 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;1*</italic>
###xml 964 966 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 973 974 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-</italic>
###xml 977 984 965 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF*A2 </italic>
###xml 1056 1058 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1104 1107 1092 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1127 1131 1115 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 1190 1194 1178 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 1206 1208 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1226 1233 1214 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;</italic>
###xml 1238 1243 1223 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 1250 1256 1235 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4*</italic>
###xml 1387 1392 1372 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
###xml 1449 1451 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1531 1536 1516 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*</italic>
Trios 1 and 2 have striking similarities that may determine their MS-predisposing properties due to dysregulation of inflammatory pathways by protein products encoded by their genes. First, both trios include the allele G of the gene for co-stimulatory molecule CTLA4, which is an important inhibitor of T-cell activation [39]. Carriers of the +49CTLA4*G allele in exon 1, coding for the peptide leader sequence, are characterized by a reduced CTLA4 inhibitory function [40], i.e. by impaired negative regulation of the immune response. Second, both trios include alleles of cytokine genes which promote inflammatory immune response owing to decreased level of antiinflammatory cytokine TGFbeta1 (trio 1) or increased level of proinflammatory cytokine TNF (trio 2). Indeed, it is known that the circulating concentration of TGFbeta1 is under genetic control, being lower in carriers of the promoter -509TGFbeta1*C allele, in comparison with -509TGFbeta1*T allele [41]. The -308TNF*A2 allele included in trio 2 is more actively transcribed than -308TNF*A1 [42]. The sequence of the promoter region of -238TNF*B1, another trio 2 TNF allele, suggests that it is also associated with increased TNF expression [43]. In trio 1 (-509TGFbeta1*C, DRB1*18(3), CTLA4*G) carriers, a two-hit repression of negative regulation of the immune response is coupled with a contribution of the HLA class II DRB1*18(3), which is not associated alone with MS (see Figure 2A). Characteristics of autoantigen presentation in MS by the products encoded by DRB1*18(3) have not been studied; however, it is clear that presence of this allele in trio 1 may be an important factor of the individual immune response regulation, supplementing effects provided by two other alleles of the trio.
###end p 60
###begin p 61
Our results support the notion that genetic susceptibility to MS arises as a result of contribution of several predisposing alleles involved in the autoimmune inflammatory response. The nature of the interplay between the alleles in the trios remains unclear. If it arises as a result of a cumulative effect of multiple hits, these patterns provide a picture of small, individually insufficient changes combining to provide an overall significant response leading to predisposition to MS. However, this scenario does not exclude possible epistatic interactions of genes involved in the trios.
###end p 61
###begin title 62
Conclusion
###end title 62
###begin p 63
###xml 367 375 <span type="species:ncbi:9606">patients</span>
The results presented here provide the first identification of a combination of more than two alleles conferring a genetic predisposition to MS as a complex polygenic disease. The two newly identified trios perfectly separate cases from controls, at least in the present sample, as would occur in a classic monogenic dominant disease, where all observed carriers are patients. Because of sample size limitations, the result can only be considered as preliminary. However, the biological properties of the genes included in the identified trios suggest a coherent picture of dysregulation of inflammatory pathways, implying the validity of the MS-associated patterns and encouraging efforts required to replicate associations in independent data. The APSampler algorithm used to identify the predisposing patterns is highly efficient, as it requires only hours of computation time on a laptop computer for this data set, and is flexible, as it can handle incomplete genotypic information. The algorithm provides a valuable resource for the growing volume of polygenic disease-related genomic data, allowing efficient exploration of such data to identify genetic predisposition and potential therapeutic targets.
###end p 63
###begin title 64
Competing interests
###end title 64
###begin p 65
The author(s) declare that they have no competing interests.
###end p 65
###begin title 66
Authors' contributions
###end title 66
###begin p 67
###xml 295 303 <span type="species:ncbi:9606">patients</span>
OOF and MFO set up the initial formulation of the problem. OOF organized the interaction between the medical, genetic and algorithmic groups. OOF, AVF, GP and MFO wrote the manuscript. AVF and MFO conceived of and developed the algorithm and the software. ANB and EIG diagnosed MS and recruited patients. ANB, MAS and TVA recruited healthy controls. ANB, EIG and OOF selected the candidate genes. TVA, MAS, ADA, and OGK performed genotyping analysis. OGK, MAS and OOF interpreted the patterns identified by the algorithm. MAS, TVA and AVF applied the software to the genotyping database developed by TVA. GP provided expert statistical advice used to significantly improve the algorithm.
###end p 67
###begin title 68
Pre-publication history
###end title 68
###begin p 69
The pre-publication history for this paper can be accessed here:
###end p 69
###begin p 70

###end p 70
###begin title 71
Supplementary Material
###end title 71
###begin title 72
Additional File 1
###end title 72
###begin p 73
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Additional Figure 1 &#8211; TNFa/TNFb haplotype frequencies in MS patients and controls </bold>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Additional Figure 1 - TNFa/TNFb haplotype frequencies in MS patients and controls . Haplotypes are designated in accordance with TNFa/TNFb allele names.
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Additional File 2
###end title 75
###begin p 76
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Additional Figure 2 &#8211; <italic>DRB1</italic>/TNFa haplotype frequencies in MS patients and controls </bold>
###xml 84 87 84 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A: </bold>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 113 116 113 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
Additional Figure 2 - DRB1/TNFa haplotype frequencies in MS patients and controls . A: DRB1*01 -DRB1*03 alleles; B: DRB1*04 -DRB1*09 alleles. Haplotypes are designated in accordance with DRB1/TNFa allele names. Haplotypes with frequencies less than 0.5% both in MS patients and in controls are not shown.
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Additional File 3
###end title 78
###begin p 79
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT </italic>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Additional Figure 3 &#8211; <italic>TNF/LT </italic>haplotypes in MS patients and controls</bold>
###xml 69 72 69 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A: </bold>
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT </italic>
###xml 199 202 199 202 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 272 279 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT </italic>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT </italic>
###xml 423 424 423 424 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
Additional Figure 3 - TNF/LT haplotypes in MS patients and controls. A: TNF/LT haplotype frequencies in all MS patients and controls; haplotype designations and entering SNP alleles are shown below. B: Frequencies of extended haplotypes including DRB1*15(2) and different TNF/LT haplotypes in all MS patients and controls. Haplotypes are marked in accordance with DRB1 allele name and TNF/LT haplotype designation given in A. For better visualization, the same axis scales were used.
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Additional File 4
###end title 81
###begin p 82
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Additional Table 1 - Phenotypic frequencies (%) of SNP alleles in Russian MS patients and healthy individuals
###end p 82
###begin p 83
Click here for file
###end p 83
###begin title 84
Acknowledgements
###end title 84
###begin p 85
We thank Erica Golemis and Kenneth Morgan for very useful discussion and for advice. All authors from Russia thank Russian Foundation for Basic Research (05-04-48982-a and 04-04-49601-a). AVF thanks the Howard Hughes Medical Institute (55005610), the Ludwig Institute for Cancer Research (CRDF 12039), Russian Ministry of Science and Education (State Contract # 02.434.11008) and Russian Academy of Sciences Presidium Program in Molecular and Cellular Biology. GP thanks NSF (DMS034211) and NCI (CA06973). MFO thanks NCI (support under CCSG grant CA06927), the National Library of Medicine (LM008932), and the Pennsylvania Department of Health for support.
###end p 85
###begin article-title 86
Genome-wide association studies for common diseases and complex traits
###end article-title 86
###begin article-title 87
###xml 25 30 <span type="species:ncbi:9606">human</span>
Genetics, statistics and human disease: analytical retooling for complexity
###end article-title 87
###begin article-title 88
Genetic dissection of complex and quantitative traits: from fantasy to reality via a community effort
###end article-title 88
###begin article-title 89
New approaches to investigating heterogeneity in complex traits
###end article-title 89
###begin article-title 90
Progress in deciphering the genetics of multiple sclerosis
###end article-title 90
###begin article-title 91
Genetics of multiple sclerosis: determinants of autoimmunity and neurodegeneration
###end article-title 91
###begin article-title 92
A second-generation genomic screen for multiple sclerosis
###end article-title 92
###begin article-title 93
A high-density screen for linkage in multiple sclerosis
###end article-title 93
###begin article-title 94
A meta-analysis of whole genome linkage screens in multiple sclerosis
###end article-title 94
###begin article-title 95
The genetic epidemiology of multiple sclerosis
###end article-title 95
###begin article-title 96
Searching for genetic determinants in the new millennium
###end article-title 96
###begin article-title 97
Genetics of multiple sclerosis
###end article-title 97
###begin article-title 98
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients
###end article-title 98
###begin article-title 99
TCR beta polymorphisms and multiple sclerosis
###end article-title 99
###begin article-title 100
The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians
###end article-title 100
###begin article-title 101
Sequence variation in the transforming growth factor-beta1 (TGFB1) gene and multiple sclerosis susceptibility
###end article-title 101
###begin article-title 102
Myelin basic protein gene is associated with MS in DR4- and DR5-positive Italians and Russians
###end article-title 102
###begin article-title 103
Analysis of IL4R haplotypes in predisposition to multiple sclerosis
###end article-title 103
###begin article-title 104
Intercellular adhesion molecule-1 K469E polymorphism: study of association with multiple sclerosis
###end article-title 104
###begin article-title 105
A Markov Chain Monte Carlo Technique for Identification of Combinations of Allelic Variants Underlying Complex Diseases
###end article-title 105
###begin article-title 106
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis
###end article-title 106
###begin article-title 107
Connection of multiple sclerosis in the Russian population with alleles of the major histocompatibility complex DRB1 gene
###end article-title 107
###begin article-title 108
###xml 33 38 <span type="species:ncbi:9606">human</span>
DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene
###end article-title 108
###begin article-title 109
Polymorphisms in the TNF gene cluster and MHC serotypes in the West of Scotland
###end article-title 109
###begin article-title 110
Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis
###end article-title 110
###begin article-title 111
GeneFisher
###end article-title 111
###begin article-title 112
Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA
###end article-title 112
###begin article-title 113
Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study
###end article-title 113
###begin article-title 114
Direct PCR of small genomic DNA fragments from serum
###end article-title 114
###begin article-title 115
Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups
###end article-title 115
###begin article-title 116
Equations of state calculations by fast computing machines
###end article-title 116
###begin article-title 117
Empirical Bayes Analysis of a Microarray Experiment
###end article-title 117
###begin article-title 118
Association and linkage of juvenile MS with HLA-DR2(15) in Russians
###end article-title 118
###begin article-title 119
TNF gene polymorphisms: associations with multiple sclerosis susceptibility and severity
###end article-title 119
###begin article-title 120
Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region
###end article-title 120
###begin article-title 121
T-cell regulation by CD28 and CTLA-4
###end article-title 121
###begin article-title 122
###xml 22 27 <span type="species:ncbi:9606">human</span>
A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation
###end article-title 122
###begin article-title 123
Genetic control of the circulating concentration of transforming growth factor type beta1
###end article-title 123
###begin article-title 124
Genotyping for cytokine polymorphisms: allele frequencies in the Italian population
###end article-title 124
###begin article-title 125
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis
###end article-title 125
###begin article-title 126
Nomenclature for factors of the HLA system, 2002
###end article-title 126

